Linagliptin+metformin Stada

Linagliptin, the active ingredient in Linagliptin+metformin Stada, is a DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH USA supplies Linagliptin+metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is distributed under strict regulatory compliance.

Linagliptin+metformin Stada is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise. Inadequate control on metformin monotherapy: provides additional glucose lowering through DPP‑4 inhibition. Combination therapy with other oral antidiabetics: offers synergistic effect to achieve target HbA1c levels.

The combination may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal discomfort) - Diarrhea - Headache - Mild hypoglycemia when used with sulfonylureas or insulin

Serious or Rare Side Effects: - Lactic acidosis (especially in renal impairment) - Acute pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, Stevens‑Johnson syndrome) - Hepatic failure - Persistent severe hypoglycemia

When prescribing Linagliptin+metformin Stada, clinicians should consider several precautionary measures.

Renal function: assess eGFR before initiation and monitor periodically. Hepatic function: evaluate liver enzymes as metformin is contraindicated in severe hepatic disease. Lactic acidosis risk: avoid in patients with significant renal impairment or conditions predisposing to hypoxia. Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. Drug interactions: review concomitant medications that may affect renal clearance or increase hypoglycemia. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Linagliptin+metformin Stada can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Severe renal impairment: increases risk of metformin‑associated lactic acidosis. - Concurrent use with iodinated contrast agents: may precipitate acute kidney injury. - Co‑administration with insulin or sulfonylureas: may cause profound hypoglycemia.

Moderate Interactions (Monitor Closely): - Cimetidine: can raise linagliptin plasma concentrations. - Diuretics (e.g., thiazides): may affect renal function and metformin clearance. - Alcohol intake: can potentiate metformin‑related lactic acidosis risk.